Koltan names Frank Karbe to board
This article was originally published in Scrip
New Haven, Connecticut-based Koltan Pharmaceuticals has named Frank Karbe, former chief financial officer of Exelixis, to its board of directors. Mr Karbe has more than two decades of international experience in finance and business development. Previously, Mr Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. And since January 2010, he has been a member of the board and chair of the audit committee for Tekmira Pharmaceuticals, a publicly held biopharmaceutical company.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.